Currently, multiple phase 3 programs evaluating disparate GLP-1 RAs (eg, semaglutide, brenipatide [GLP-GIP agonists]) are ongoing, with results expected to appear over the next 1 to 3 years (NCT07219953, NCT07286175, NCT07412756, NCT07410507)
These providers can rule out other causes (thyroid dysfunction, pregnancy, underlying reproductive conditions) and confirm whether tirzepatide adjustment or dose slowing might help
The bundle provides greater research capacity, making it suitable for extended studies, repeatability testing, comparative investigations, and multi-phase laboratory protocols
Though the policy could create savings in the long-term, CMS did not assume downstream savings in the proposed rule
Refrigerate reconstituted vials at 28C